Clinical trial · Observational
Development of a Pan-Cancer Screening Model Based on Blood Biomarkers
Establishment of a Pan-Cancer Screening Model Based on Blood Biomarkers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to develop a pan-cancer screening model using routine blood biomarkers (including complete blood count, biochemical tests, coagulation panel, and tumor markers). The study is retrospective, collecting data from approximately 10,000,000 cancer patients diagnosed at multiple centers in China between January 2006 and September 2025. All patients have confirmed pathological diagnosis and complete blood test records. A Mixture of Experts (MoE) machine learning model will be built to predict the presence of various cancers (e.g., gastric, colorectal, liver, lung, ovarian cancer). The goal is to establish a low-cost, non-invasive screening tool suitable for large-scale population screening.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All Participants
- description
- All enrolled individuals (cancer patients and non-cancer controls) with retrospective blood biomarker data.
- interventionNames
- Other: No intervention
Primary outcomes (3)
- measure
- Area under the ROC curve (AUC)
- timeFrame
- At study completion, approximately December 2030
- description
- AUC of the MoE model for discriminating cancer from non-cancer controls.
- measure
- Sensitivity of the model
- timeFrame
- At study completion, approximately December 2030
- description
- True positive rate of the pan-cancer screening model.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed cancer patients (for case group) OR individuals without cancer (for control group) * Age between 18 and 80 years * Complete clinical data and blood test results (complete blood count, biochemistry, coagulation panel, tumor markers) available * No history of other organic diseases (excluding cancer) Exclusion Criteria: * Presence of organic diseases other than cancer (e.g., severe heart, liver, kidney disease) * Hematologic disorders or immunodeficiency diseases (e.g., AIDS) * Incomplete data or missing timeline records
References
Publications (0)
Data not yet available